NCDHHS and CMS collaborate on the CGT Access Model to increase sickle cell disease gene therapy access and lower costs for Medicaid patients.
NCDHHS and CMS collaborate to enhance sickle cell disease gene therapy access for Medicaid patients. The FDA approved Casgevy and Lyfgenia therapies, which cost over $2 million per person, pose challenges for Medicaid budgeting. The CGT Access Model aims to increase therapy access, lower costs, and mitigate expenses. An application will be submitted to CMS in summer, with potential benefits as early as 2025.
February 23, 2024
4 Articles